Phase 1/1b Study of CER-1236 in Relapsed/Refractory AML and TP53-mutated or MRD-Positive Disease

CERo Therapeutics Holdings, Inc. is evaluating CER-1236—an autologous chimeric engulfment receptor T-cell therapy—in a first-in-human, open-label phase 1/1b study for patients with relapsed/refractory AML, including those with measurable residual disease and TP53 mutations. Patients receive a single infusion of CER-1236 following lymphodepletion with cyclophosphamide, fludarabine, and mesna.